Biotech Business Daily (BTRX, BMRN, DSCO, ENDP, MNKD, MIPI, QSC, TECH)
Analysts expected losses of $0.05 EPS. Earnings were driven primarily by sales of enzyme replacement therapy Naglazyme. The company communicated confidence that any regulatory concerns have been ironed out and this third FDA result will be positive.
Sources:
- www.247wallst.com
- www.onlinetradersforum.com
- stock-promoter.thesubway.com
- rosesryellow.blogspot.com
- www.boardcentral.com
- dandelionseedco.blogspot.com
Tags: agrium, confidence, discovery labs, dsco, dzien flagi, earnings, enzyme replacement therapy, fda, losses, mon, regulatory concerns, yahoo